XmAb 7195

Drug Profile

XmAb 7195

Alternative Names: XmAb® 7195

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xencor
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor antagonists; Immunoglobulin E inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma; Hypersensitivity

Most Recent Events

  • 24 Feb 2017 Xencor completes phase Ib trials in Allergic asthma in USA (SC) (NCT02881853)
  • 24 Feb 2017 Xencor completes phase Ib trials in Hypersensitivity in USA (SC) (NCT02881853)
  • 15 Sep 2016 Phase-I clinical trials in Allergic asthma in USA (SC) (NCT02881853)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top